<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398824</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00026540</org_study_id>
    <nct_id>NCT03398824</nct_id>
  </id_info>
  <brief_title>Pilot Study of Metformin for Patients With Fanconi Anemia</brief_title>
  <official_title>Pilot Study of Metformin for Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution, open-label, single arm pilot study of Metformin in patients&#xD;
      with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response.&#xD;
      This study will also assess safety, tolerability, and the biologic effects of Metformin in&#xD;
      patients with FA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved hematologic response</measure>
    <time_frame>6 months</time_frame>
    <description>Hematologic response is defined by specific increases in erythroid, platelet, and neutrophil counts.&#xD;
Erythroid response: Hemoglobin (Hgb) increase by &gt;1.5g/dL for non-transfusion dependent patients and for patients who are transfusion dependent: Transfusion independence Only transfusions given for Hgb ≤8g/dL or for symptoms will be counted in the response evaluation&#xD;
Platelet response: If initially &lt;20k/uL to start, then must increase to &gt;20k/UL with an absolute increase of 100%. If initially ≥20k/uL to start, then must have an absolute increase of &gt;30k/UL&#xD;
Neutrophil response: If initially &lt;500/uL to start, then must increase to &gt;500/uL with an absolute increase of &gt; 250/uL. If initially ≥500/uL to start, then must have an absolute increase of &gt;500/uL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive metformin HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin HCl</intervention_name>
    <description>Receive metformin HCl</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 6 years and ≤35 years&#xD;
&#xD;
          -  Lansky/Karnofsky performance status ≥ 50% for patients ≥16 years of age and Lansky ≥&#xD;
             50% for patients &lt;16 years of age (see Appendix A)&#xD;
&#xD;
          -  Diagnosis requirement&#xD;
&#xD;
          -  Participants must have a clinical diagnosis of Fanconi Anemia.&#xD;
&#xD;
               -  Participants must have confirmed diepoxybutane-mitomycin C (DEB/MMC) stress&#xD;
                  testing to document diagnosis of Fanconi Anemia.&#xD;
&#xD;
               -  Patients must have at least one of the following cytopenias: Hemoglobin &lt;10g/dL;&#xD;
                  Platelets &lt;100k/uL; Absolute neutrophil count &lt;1000/uL&#xD;
&#xD;
          -  Participants must have normal organ function as defined below:&#xD;
&#xD;
               -  Hepatic Function : Total bilirubin ≤ 1.5 x upper limit of normal for age; alanine&#xD;
                  aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 135 U/L&#xD;
&#xD;
               -  Renal Function: A serum creatinine based on age/gender as follows:&#xD;
&#xD;
        Age Maximum Serum Creatinine (mg/dL) Male Female&#xD;
&#xD;
          1. to &lt; 2 years 0.6 0.6&#xD;
&#xD;
          2. to &lt; 6 years 0.8 0.8&#xD;
&#xD;
        6 to &lt; 10 years 1 1 10 to &lt; 13 years 1.2 1.2 13 to &lt; 16 years 1.5 1.4&#xD;
&#xD;
        ≥ 16 years 1.7 1.4&#xD;
&#xD;
        AND&#xD;
&#xD;
        • Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above&#xD;
        institutional normal&#xD;
&#xD;
          -  Normal cardiac status as documented clinically, otherwise they will need an&#xD;
             echocardiogram prior to enrollment&#xD;
&#xD;
          -  Serum bicarbonate must be &gt;17.&#xD;
&#xD;
          -  Participants of child-bearing or child-fathering potential must agree to use adequate&#xD;
             contraception (hormonal birth control; intrauterine device; double barrier method; or&#xD;
             total abstinence) throughout their participation, including up until 30 days after&#xD;
             last dose of Metformin.&#xD;
&#xD;
          -  Patients must be able to swallow pills.&#xD;
&#xD;
          -  Ability to understand and/or the willingness of the patient (or parent or legally&#xD;
             authorized representative, if minor) to provide informed consent, documented using an&#xD;
             institutionally approved informed consent procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have undergone prior bone marrow transplantation.&#xD;
&#xD;
          -  Patients must not have very severe aplastic anemia at the time of enrollment which&#xD;
             would require bone marrow transplantation (as defined by at least 2 out of the&#xD;
             following 3: Absolute Neutrophil Count (ANC) &lt;200k/uL, platelets &lt;20k/uL, absolute&#xD;
             reticulocyte count &lt;40k/uL).&#xD;
&#xD;
          -  Patients must not be taking any other concurrent medications to improve their&#xD;
             hematopoiesis such as androgens or growth factors such as Granulocyte&#xD;
             colony-stimulating factor (G-CSF), erythropoietin (EPO), or thrombopoietin (TPO)&#xD;
             mimetics. There is a one month wash-out period for prior therapies including&#xD;
             androgens.&#xD;
&#xD;
          -  Pregnant participants will not be entered on this study given that the effects of&#xD;
             Metformin on the developing human fetus are unknown.&#xD;
&#xD;
          -  Breastfeeding mothers are not eligible because there is an unknown but potential risk&#xD;
             for adverse events in nursing infants secondary to treatment of the mother with&#xD;
             Metformin.&#xD;
&#xD;
          -  Patients must not have a history of allergic reactions attributed to compounds of&#xD;
             similar chemical or biologic composition to Metformin.&#xD;
&#xD;
          -  Patients must not have uncontrolled intercurrent illness including, but not limited&#xD;
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Patients must not have prior history of symptomatic hypoglycemia over the past year or&#xD;
             hypoglycemia with glucose &lt;50mg/dL on screening and baseline laboratory assessments.&#xD;
&#xD;
          -  Patients must not have type 1 diabetes mellitus.&#xD;
&#xD;
          -  Patients must abstain from alcohol as part of this study.&#xD;
&#xD;
          -  Patients must not have a diagnosis of myelodysplastic syndrome or leukemia, or other&#xD;
             concurrent malignancy undergoing treatment.&#xD;
&#xD;
          -  Patients must not have vitamin B12 deficiency.&#xD;
&#xD;
          -  Patients must not have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akiko Shimamura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Elissa Furutani, MD</investigator_full_name>
    <investigator_title>Instructor in Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Fanconi Anemia</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

